The full name

email@vos.com

Top Biotech News (04 Apr 2025)

Top Biotech News (04 Apr 2025)

EU Extends Welcome to US Scientists Amid Academic-Freedom Concerns

Summary:

New EU Research Commissioner Zaharieva announces initiatives to attract American researchers fleeing political pressures, including dedicated programs, funding, and visa reforms while prioritizing protection of scientific freedom.

75% of US Scientists Consider Leaving Amid Trump Policies

Summary:

Nature poll reveals researchers, especially early-career scientists, looking to relocate to Europe and Canada as funding cuts and administrative chaos disrupt America’s scientific community.

AI Revolution in Protein Sequencing Opens New Frontiers

Summary:

InstaNova and other AI tools now identify proteins without database searches, enabling discoveries in archaeology, medicine, and environmental science by recognizing unknown protein sequences through deep learning techniques.

Stocks Plunge as FDA’s Key Vaccine Official Forced Out

Summary:

Industry in shock after Peter Marks’ departure, orchestrated by Kennedy’s HHS and new FDA head Makary, triggers market sell-off with gene therapy and vaccine companies hit hardest.

Lilly’s RNA Drug Shows Promise in Heart Disease Treatment

Summary:

New drug lepodisiran reduces harmful lipoprotein(a) levels by 94%, potentially creating a third pillar for cardiovascular risk management alongside cholesterol and triglyceride treatments. Clinical benefit remains unproven.

Subscribe
to the latest updates in the newsletter

Related Solutions

organoEZ

  • Chemical
  • ECM
  • Media
  • Protein
organoEZ

Organoid Service

  • Disease Modeling
  • Oncology
  • Organoid
Organoid Service

Research service

  • Cosmetics
  • OECD TG
  • Zebrafish
Research service

Technical service

  • Bioinfomatics
  • Holotomography
  • Molecular biology
  • Spatial Biology
Technical service

Next Articles

Connect with Us

By submitting your details, you confirm that you have reviewed and agree with the Lambda Biologics Privacy Policy.